BioNTech's Phase 2/3 Trial of BNT113 in Head, Neck Cancer Fails to Meet Progression-Free Survival Endpoint

MT newswire2026/10/13 11:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

07:08 AM EDT, 10/13/2026 (MT Newswires) -- BioNTech's (BNTX) phase 2/3 trial of BNT113, combined with pembrolizumab, in head and neck cancer failed to meet one of its two primary endpoints, the company said Tuesday. The study's primary endpoints are progression-free survival and overall survival, and the combination therapy did not demonstrate a statistically significant improvement in progression-free survival, BioNTech said. The trial compares the combination therapy with pembrolizumab alone, the company added. BioNTech plans to continue the trial to evaluate the second primary endpoint, according to the statement. Shares of BioNTech were down more than 2% premarket Tuesday.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

The three co-founders of CoreWeave have cumulatively cashed out over $3.3 billion since the company went public, while its current stock price has plummeted more than 50% from its peak. At present, the company's bonds maturing in 2032 have fallen into distressed territory, with CDS spreads surging to 1,117 basis points, implying a default probability of 63%. Market concerns about its ability to repay debt are now spreading along the financing chain of AI computing power leasing.

华尔街见闻•2026/10/16 13:15

BRIEF-Union Pacific CFO Jennifer Hamann To Step Down

Reuters•2026/10/16 13:02

BUZZ - Property insurance company Travelers' stock price drops due to increased catastrophe losses caused by severe storms.

路透社•2026/10/16 13:01